Clotprotect Therapeutics secures £600k seed funding for trauma treatment

A first-in-class small molecule anti-fibrinolytic treatment for traumatic haemorrhage is being developed by Clotprotect Therapeutics Limited following an estimated £600k seed funding round. The Leeds-based company reached a post-money valuation of £7m through this investment.

Clotprotect Therapeutics Limited operates as a spin-out from the University of Leeds. The company focuses on the development of a direct plasmin inhibitor designed to treat acute bleeding and traumatic haemorrhage. This medical technology targets trauma and surgical patients by providing an alternative to current standards of care for controlling blood loss. The therapeutic approach involves using small molecules to inhibit plasmin directly, which is a key component in the body's process of breaking down blood clots.

The business was incorporated in 2024 and currently reports a headcount of one employee. This seed round follows the company's initial formation to commercialise research into natural sciences and engineering. Documentation for the share allotment was completed in February, with formal filings processed in March.

The £600k investment provides the capital necessary to progress the company's small molecule therapeutics through the early stages of development. Clotprotect Therapeutics Limited aims to address specific needs within the medical market for effective haemorrhage control in emergency and clinical settings. The £7m valuation reflects the company's position as an early-stage biotechnology firm transitioning from university research to commercial development.